SIREN : 521813840
VAPHARM is a French company founded 16 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in CERGY (95800), this company of category PME shows in 2023 a revenue of 2.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 837 043 € | 2 734 368 € | 2 642 979 € | 2 507 694 € | 2 469 645 € | 2 577 835 € | N/C | N/C | 2 758 168 € |
| Net income | 186 465 € | 175 813 € | 220 834 € | 194 146 € | 177 343 € | 274 200 € | -28 924 € | 91 917 € | 227 664 € |
| EBITDA | 263 348 € | 264 780 € | 326 172 € | 298 087 € | 277 478 € | 368 183 € | N/C | N/C | 353 869 € |
| Net margin | 6.6% | 6.4% | 8.4% | 7.7% | 7.2% | 10.6% | N/C | N/C | 8.3% |
In 2023, VAPHARM achieves revenue of 2.8 M€. Revenue is growing positively over 9 years (CAGR: +0.4%). Vs 2022: +4%. After deducting consumption (2.0 M€), gross margin stands at 872 k€, i.e. a rate of 31%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 263 k€, representing 9.3% of revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 186 k€, i.e. 6.6% of revenue. This profit can be retained or distributed to shareholders.
2 837 043 €
871 533 €
263 348 €
260 261 €
186 465 €
9.3%
The debt ratio (= Financial debt / Equity x 100) stands at 65%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 36%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.2 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 6.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
64.656%
36.479%
6.653%
2.214
4.6%
In 2023, the debt ratio of VAPHARM (64.66) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2023, the financial autonomy of VAPHARM (36.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2023, the repayment capacity of VAPHARM (2.21) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 124.27. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 13.3x. Operating income very largely covers interest expenses: high safety margin.
124.273
13.302
In 2023, the liquidity ratio of VAPHARM (124.27) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2023, the interest coverage of VAPHARM (13.3x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 54 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 96 days. Excellent situation: suppliers finance 42 days of the operating cycle (retail model). Inventory turnover is 30 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 80 days of revenue, i.e. 631 k€ to permanently finance. Notable WCR improvement over the period (-44%), freeing up cash.
631 072 €
54 j
96 j
30 j
80 j
Based on 220 transactions of similar company sales in 2023, the value of VAPHARM is estimated at 2 337 332 € (range 1 475 859€ - 3 015 341€). With an EBITDA of 263 348€, the sector multiple of 10.0x is applied. The price/revenue ratio is 0.69x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare VAPHARM with other companies in the same sector:
The revenue of VAPHARM in 2023 is 2.8 M€.
Yes, VAPHARM generated a net profit of 186 k€ in 2023.
The headquarters of VAPHARM is located in CERGY (95800), in the department Val-d'Oise.
The tax return of VAPHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
VAPHARM operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.